Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Qini Zhao, Haiming Xu, Lirong Zhang, Long Liu & Libo Wang. (2019) RETRACTED ARTICLE: GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response. Artificial Cells, Nanomedicine, and Biotechnology 47:1, pages 2325-2332.
Read now
Read now
Agostino Consoli & Gloria Formoso. (2015) Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opinion on Drug Safety 14:2, pages 207-218.
Read now
Read now
André J Scheen. (2014) Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 839-857.
Read now
Read now
Articles from other publishers (18)
Hyeon Seok Oh, Eun Ji Park, Tae Suk Lee, Yejin An, Tae Hwan Kim, Soyoung Shin & Beom Soo Shin. (2023) Pharmacokinetics of Lixisenatide, a GLP-1 Receptor Agonist, Determined by a Novel Liquid Chromatography–Tandem Mass Spectrometry Analysis in Rats. Separations 10:5, pages 282.
Crossref
Crossref
Jing-Yue Wang, Quan-Wei Wang, Xin-Yu Yang, Wei Yang, Dong-Rui Li, Jing-Yu Jin, Hui-Cong Zhang & Xian-Feng Zhang. (2023) GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology 14.
Crossref
Crossref
Débora Luiza Quintilhano, Daniele Romani Miksza, Winny Beatriz de Souza Galia, Mahira Oliveira Ramalho Costa Ramalho, Camila Ferraz Lucena, Maíra Mello Rezende Valle, Maria Fernanda Rodrigues Graciano, Helenir Medri de Souza & Gisele Lopes Bertolini. (2020) Insulin secretion decline in Walker-256 tumor-bearing rats is early, follows the course of cachexia, and is not improved by lixisenatide. Naunyn-Schmiedeberg's Archives of Pharmacology 394:4, pages 697-705.
Crossref
Crossref
Débora L. Quintilhano, Daniele R. Miksza, Giuliana R. Biazi, Isabele G. Frasson‐Uemura, Maria Fernanda R. Graciano, Tânia L. Mazzuco, Ângelo R. Carpinelli, Helenir M. de Souza & Gisele L. Bertolini. (2020) Effects of lixisenatide treatment on mild cachexia and related metabolic abnormalities in Walker‐256 tumour‐bearing rats. Cell Biochemistry and Function 39:2, pages 335-343.
Crossref
Crossref
Alexandros Sachinidis, Dragana Nikolic, Anca Pantea Stoian, Nikolaos Papanas, Omer Tarar, Ali A. Rizvi & Manfredi Rizzo. (2020) Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism 111, pages 154343.
Crossref
Crossref
Juris J. Meier, Björn A. Menge, Nina Schenker, Silke Erdmann, Melanie Kahle‐Stephan, Freimut Schliess, Christoph Kapitza & Michael A. Nauck. (2019) Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal‐related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 22:4, pages 599-611.
Crossref
Crossref
Mochao Xiao, Daifeng Lu, Jiali Tian, Yang Yu, Qin Zhang, Lili Zhang & Dong Chang. (2020) The protective effects of GLP-1 receptor agonist lixisenatide on oxygen-glucose deprivation/reperfusion (OGD/R)-induced deregulation of endothelial tube formation. RSC Advances 10:17, pages 10245-10253.
Crossref
Crossref
Marie-Noel Rahhal, Naser Eddin Gharaibeh, Leili Rahimi & Faramarz Ismail-Beigi. (2019) Disturbances in Insulin–Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes. The Journal of Clinical Endocrinology & Metabolism 104:11, pages 4949-4966.
Crossref
Crossref
Zhen-gang Wei, Man-cai Wang, Hui-han Zhang, Zhe-yuan Wang, Gen-nian Wang, Feng-xian Wei, Ya-wu Zhang, Xiao-dong Xu & You-cheng Zhang. (2018) PRISMA—efficacy and safety of lixisenatide for type 2 diabetes mellitus. Medicine 97:51, pages e13710.
Crossref
Crossref
Manfredi Rizzo, Dragana Nikolic, Angelo Maria Patti, Carlo Mannina, Giuseppe Montalto, Brooke S. McAdams, Ali A. Rizvi & Francesco Cosentino. (2018) GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864:9, pages 2814-2821.
Crossref
Crossref
Rania G. Abdel-latif, Gehan H. Heeba, Ashraf Taye & Mohamed M.A. Khalifa. (2018) Lixisenatide ameliorates cerebral ischemia-reperfusion injury via GLP-1 receptor dependent/independent pathways. European Journal of Pharmacology 833, pages 145-154.
Crossref
Crossref
Baptist Gallwitz. 2016. Handbook of Incretin-based Therapies in Type 2 Diabetes. Handbook of Incretin-based Therapies in Type 2 Diabetes
31
43
.
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:12, pages 1225-1238.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
Rhonda Bentley-Lewis, David Aguilar, Matthew C. Riddle, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C. Gerstein, Peter Johnston, Lars V. Køber, Francesca Lawson, Eldrin F. Lewis, Aldo P. Maggioni, John J.V. McMurray, Lin Ping, Jeffrey L. Probstfield, Scott D. Solomon, Jean-Claude Tardif, Yujun Wu & Marc A. Pfeffer. (2015) Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal 169:5, pages 631-638.e7.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes. Clinical Pharmacokinetics 54:1, pages 1-21.
Crossref
Crossref
Stefan Engeli & Jens Jordan. (2014) Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors. Current Opinion in Nephrology and Hypertension 23:5, pages 468-472.
Crossref
Crossref
André J. Scheen. (2014) Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus. Clinical Pharmacokinetics 53:9, pages 773-785.
Crossref
Crossref